171 related articles for article (PubMed ID: 35996199)
1. Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients.
Xi Y; Jin C; Liu W; Zhou H; Wang Z; Zhou R; Lou S; Zhao X; Chen F; Cheng P; Sun Z; Jia H; Zhang L
Haemophilia; 2022 Nov; 28(6):e219-e227. PubMed ID: 35996199
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: A multicentre, single-arm trial.
Sun Z; Xi Y; Liu W; Yang L; Wang X; Jin C; Jia H; Zhang L
Haemophilia; 2023 Jul; 29(4):997-1004. PubMed ID: 36913439
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
Xue F; Zhao X; Sun J; Zeng X; Yang F; Xu M; Yu Z; Gu W; Feng Y; Li W; Zheng C; Bi H; Xie L; Gai W; Yang R
Haemophilia; 2021 Sep; 27(5):814-822. PubMed ID: 34089210
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study.
Holme PA; Poulsen LH; Tueckmantel C; Maas Enriquez M; Alvarez Román MT; De Cristofaro R
Haemophilia; 2024 Mar; 30(2):388-394. PubMed ID: 38229269
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
Reding MT; Ng HJ; Poulsen LH; Eyster ME; Pabinger I; Shin HJ; Walsch R; Lederman M; Wang M; Hardtke M; Michaels LA
J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
10. PK-guided personalized prophylaxis with Nuwiq
Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
[TBL] [Abstract][Full Text] [Related]
11. Break-through bleeding in relation to pharmacokinetics of Factor VIII in paediatric patients with severe haemophilia A.
Cheng X; Li P; Chen Z; Zhang N; Zhen Y; Zhao L; Wang X; Wu R
Haemophilia; 2018 Jan; 24(1):120-125. PubMed ID: 29194866
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
13. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
[TBL] [Abstract][Full Text] [Related]
14. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
[TBL] [Abstract][Full Text] [Related]
15. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
Shah A; Coyle T; Lalezari S; Fischer K; Kohlstaedde B; Delesen H; Radke S; Michaels LA
Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
[TBL] [Abstract][Full Text] [Related]
16. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
17. Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq
Dargaud Y; Negrier C; Rusen L; Windyga J; Georgiev P; Bichler J; Solomon C; Knaub S; Lissitchkov T; Klamroth R
Haemophilia; 2018 Jul; 24(4):619-627. PubMed ID: 29855112
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
Saxena K; Lalezari S; Oldenburg J; Tseneklidou-Stoeter D; Beckmann H; Yoon M; Maas Enriquez M
Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
[TBL] [Abstract][Full Text] [Related]
19. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.
Négrier C; Mahlangu J; Lehle M; Chowdary P; Catalani O; Bernardi RJ; Jiménez-Yuste V; Beckermann BM; Schmitt C; Ventriglia G; Windyga J; d'Oiron R; Moorehead P; Koparkar S; Teodoro V; Shapiro AD; Oldenburg J; Hermans C
Lancet Haematol; 2023 Mar; 10(3):e168-e177. PubMed ID: 36716761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]